Cadence Pharmaceuticals Inc Quick Ratio (CADX) starting from the fourth quarter 2013 to fourth quarter 2012, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Cadence Pharmaceuticals Inc  (CADX)

Cadence Pharmaceuticals Inc's Quick Ratio

CADX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2013, Quick Ratio fell to 1.59 a new company low.

Within Biotechnology & Pharmaceuticals industry 80 other companies have achieved higher Quick Ratio than Cadence Pharmaceuticals Inc in fourth quarter 2013. While Quick Ratio total ranking in the fourth quarter 2013 has deteriorated compared to the prior quarter from 1061 to 1235.

Explain Quick Ratio?
How much Cash & cash equivalents CADX´s has?
What are CADX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CADX Quick Ratio (Dec 31 2013)
Q4		 (Sep 30 2013)
Q3		 (Jun 30 2013)
Q2		 (Mar 31 2013)
Q1		 (Dec 31 2012)
Q4
Y / Y Current Liabilities Change 74.02 % -2.53 % -2.86 % -1.56 % 35.01 %
Y / Y Cash & cash equivalent Change -7.6 % -26.84 % -37 % -40.52 % -50.88 %
Quick Ratio MRQ 1.59 1.97 2.18 3.11 2.99
CADX's Total Ranking # 1235 # 1061 # 1443 # #
Seq. Current Liabilities Change 31.5 % 5.41 % 26.19 % -0.51 % -26.34 %
Seq. Cash & cash equivalent Change 5.64 % -4.54 % -11.43 % 3.46 % -16.36 %



Quick Ratio fourth quarter 2013 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 81
Healthcare Sector # 307
Overall Market # 1235


Quick Ratio Statistics
High Average Low
2.99 2.18 1.59
(Dec 31 2012)   (Dec 31 2013)




Financial Statements
Cadence Pharmaceuticals Inc's Current Liabilities $ 37 Millions Visit CADX's Balance sheet
Cadence Pharmaceuticals Inc's Cash & cash equivalent $ 58 Millions Visit CADX's Balance sheet
Source of CADX's Sales Visit CADX's Sales by Geography


Cumulative Cadence Pharmaceuticals Inc's Quick Ratio

CADX's Quick Ratio for the trailling 12 Months

CADX Quick Ratio

 (Dec 31 2013)
12 Months		 (Sep 30 2013)
12 Months		 (Jun 30 2013)
12 Months		 (Mar 31 2013)
12 Months		 (Dec 31 2012)
12 Months
Y / Y Current Liabilities TTM Growth 14.02 % 3.92 % 8.61 % 12.16 % 21.63 %
Y / Y Cash & cash equivalent TTM Growth -30.43 % -40.46 % -34.34 % -26.45 % -20.4 %
Quick Ratio TTM 2.11 2.5 2.69 3.01 3.45
Total Ranking TTM # 2397 # 0 # 0 # #
Seq. Current Liabilities TTM Growth 16.18 % -0.74 % -0.79 % -0.34 % 5.89 %
Seq. Cash & cash equivalent TTM Growth -1.99 % -7.74 % -11.49 % -13.08 % -16.12 %

Quick ratio ranking by company, industry and sector >> Back to CADX Financial Strength Comparisons >> Go to Compare CADX Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q4 2013 to $36.54 millions, cumulative Quick Ratio decreased to 2.11 above the CADX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 40 other companies have achieved higher Quick Ratio than Cadence Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2013 from 0 to 2397.

Explain Quick Ratio?
How much Cash & cash equivalents CADX´s has?
What are CADX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 41
Healthcare Sector # 246
Within the Market # 2397


trailing twelve months Quick Ratio Statistics
High Average Low
1.44 1.44 1.44
(Dec 31 2013)  




Companies with similar Quick Ratio in the quarter ending Dec 31 2013, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2013 MRQ Cash & cash equivalentDec 31 2013 MRQ Current Liabilities
Receptos, Inc.  4.31 $ 69.490  Millions$ 16.141  Millions
Acceleron Pharma inc  4.19 $ 114.076  Millions$ 27.210  Millions
Qiagen N v   3.91 $ 472.473  Millions$ 120.834  Millions
Pluri Inc   3.84 $ 22.764  Millions$ 5.921  Millions
Seagen Inc   3.77 $ 374.267  Millions$ 99.198  Millions
Champions Oncology Inc   3.26 $ 9.561  Millions$ 2.929  Millions
Cellular Biomedicine Group Inc   3.26 $ 7.175  Millions$ 2.202  Millions
Genocea Biosciences Inc   3.24 $ 12.365  Millions$ 3.813  Millions
Protalix Biotherapeutics inc   3.24 $ 86.398  Millions$ 26.696  Millions
Exelixis Inc   2.90 $ 254.666  Millions$ 87.853  Millions
Palisade Bio Inc   2.84 $ 16.846  Millions$ 5.936  Millions
Acorda Therapeutics Inc   2.84 $ 274.205  Millions$ 96.643  Millions
Halozyme Therapeutics Inc   2.81 $ 71.503  Millions$ 25.453  Millions
Agenus Inc  2.66 $ 27.352  Millions$ 10.296  Millions
Brainstorm Cell Therapeutics inc   2.63 $ 3.503  Millions$ 1.332  Millions
Biocryst Pharmaceuticals Inc   2.50 $ 38.206  Millions$ 15.256  Millions
Amgen Inc   2.44 $ 19,401.000  Millions$ 7,947.000  Millions
Gentium S.p.a.  2.37 $ 16.154  Millions$ 6.808  Millions
Nanostring Technologies Inc   2.29 $ 42.656  Millions$ 18.630  Millions
Eiger Biopharmaceuticals Inc   2.25 $ 10.612  Millions$ 4.713  Millions
Cannabis Global Inc.  1.91 $ 0.011  Millions$ 0.006  Millions
Dendreon Corp  1.73 $ 179.622  Millions$ 103.761  Millions
Cadence Pharmaceuticals Inc  1.59 $ 57.949  Millions$ 36.543  Millions
Vericel Corporation  1.51 $ 8.059  Millions$ 5.321  Millions
Coherus Oncology inc   1.48 $ 39.604  Millions$ 26.703  Millions
Cyclo Therapeutics Inc   1.35 $ 0.269  Millions$ 0.199  Millions
Polarityte Inc   1.31 $ 12.349  Millions$ 9.399  Millions
Ladrx Corporation  1.25 $ 38.568  Millions$ 30.839  Millions
Titan Pharmaceuticals Inc   1.09 $ 11.798  Millions$ 10.846  Millions
Fennec Pharmaceuticals Inc   1.04 $ 3.326  Millions$ 3.207  Millions

Date modified: 2026-09-08T15:09:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.